HER2 expression is described in the HER2-overexpressing and luminal B subtypes, whereas triple-negative breast cancers are defined by lack of ER, PR and ERBB2 amplification[11-13]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.